Trials / Completed
CompletedNCT02780141
A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia
A Phase 3, Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in Erythropoiesis Stimulating Agent-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to evaluate the safety and efficacy of ASP1517 in ESA-naive hemodialysis chronic kidney disease patients with anemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | roxadustat | Oral |
Timeline
- Start date
- 2016-06-02
- Primary completion
- 2017-12-12
- Completion
- 2017-12-12
- First posted
- 2016-05-23
- Last updated
- 2024-10-30
Locations
47 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02780141. Inclusion in this directory is not an endorsement.